

CURRICULUM VITAE
Emina Emilia Torlakovic
Department of Pathology and Laboratory Medicine
College of Medicine

1. PERSONAL:

Born:

Place of Birth:



2. ACADEMIC CREDENTIALS:

M.D.

University of Zagreb Medical School, 1986

Diploma in Epidemiology

University of Zagreb Medical School, 1989

Ph.D.

University of Oslo Medical School, 2005

3. OTHER CREDENTIALS:

Special Licentiate

Medical Council of Canada, January 2004 – present

Diplomate

American Board of Pathology, Hematology, 2000 – present

Special Licentiate

Medical Council of Norway, January 1998 – present

Diplomate

American Board of Pathology, Anatomic and Clinical Pathology, 1996 – present

Licentiate

Minnesota Board of Medical Practice, MN, USA, 1994 – present

FLEX

USA, 1991

ECFMG

USA, 1988

Licentiate

Medical Council of Croatia, 1988 - present

4. APPOINTMENTS AND PROMOTIONS (University of Saskatchewan):

Associate Professor, Department of Pathology and Laboratory Medicine, July 2008 - Present

Assistant Professor, Without Term, Department of Pathology and Laboratory Medicine, December 2003 – July 2008

• **APPOINTMENTS (CLINICAL):**

Head/Organizer, Tumor Bank, Department of Pathology and Laboratory Medicine, Royal University Hospital, Saskatoon, SK, 2006-present.

Torlakovic, Emina Emilia
Department of Pathology and Laboratory Medicine

CV, Updated 10/2007

Director of Immunohistochemistry, Division of Anatomical Pathology, Royal University Hospital, Saskatoon, 2004 – present.

Associate Staff, Saskatoon District Health, 14 December 2003 – present.

5. ASSOCIATE MEMBERSHIP:

Associate Member, Department of Microbiology and Immunology, College of Medicine, University of Saskatchewan. 2006 – present.

Member, Genomic Medicine and Pathobiology Research Group, University of Saskatchewan. 2004 – present.

6. HONOURS:

Ernst Award in Surgical Pathology for research in diagnostic molecular pathology of MALT-lymphomas, University of Minnesota Hospital, 1995

7. PREVIOUS POSITIONS RELEVANT TO U OF S EMPLOYMENT:

1998-2003 **Senior Pathology Consultant (Overlege)**, Department of Pathology, The Norwegian Radium Hospital, Oslo, Norway.

1997-1998 **Medical Advisor (Medisinsk Rådgiver)**, Department of Pathology, The Norwegian Radium Hospital, Oslo, Norway.

1994-1996 **Surgical Pathology Fellow**, Division of Surgical Pathology, University of Minnesota Hospital, Minneapolis, MN, USA.

1993-1994 **Hematopathology Fellow**, Department of Laboratory Medicine and Pathology, Division of Special Hematology, University of Minnesota Hospital, Minneapolis, MN, USA.

1991-1993 **Anatomic/Clinical Pathology Resident**, University of Minnesota Hospital, Minneapolis, MN, USA.

1989-1991 **Anatomic/Clinical Pathology Resident**, St. Luke's/Roosevelt Hospital, Columbia University, NYC, NY, USA.

1988-1989 **Assistant Researcher**, Zagreb Center for Biomedical Research, Zagreb, Croatia.

1986-1987 **Rotating Internship**, University of Zagreb Medical School, School of Public Health, Zagreb, Croatia.

Torlakovic, Emina Emilia
Department of Pathology and Laboratory Medicine

CV, Updated 10/2007

8. TEACHING RECORD (University of Saskatchewan):

THIS INFORMATION IS INCLUDED IN TEACHING DOSSIER

9. THESES SUPERVISED:

A. Theses and Dissertations Supervised

- Nuriya Bilalovic, M.D.: **Ph.D.:** Pathology. Thesis title: "The role of PU.1 in biology of follicular lymphoma", 2004.

B. Undergraduate Research Projects

- **NK**, Sanofi-Aventis Biotalent Challenge – 2008, Saskatoon Region
- "Application of TMA technology in the study of transcription factor-target gene axis in marginal zone lymphoma" – student won two awards with this project
- **SKV**, MUM1 and CD138 phenotypes in multiple myeloma – April 2008-July 2008
- **LAL**, "PU.1 in non-Hodgkin lymphoma" – July 2008-Present

10. BOOKS, CHAPTERS IN BOOKS, EXPOSITORY AND REVIEW ARTICLES, MEDIA PRODUCTIONS:

1. Torlakovic EE, Naresh K, and Brunning RD. "Bone Marrow Immunohistochemistry", **ASCP Press, USA** (In Press)
- Five book chapters

2. Four book chapters:

Torlakovic E and Torlakovic G. In: Damjanov I, Nola M, and Rosai J. (Editors): **Rosai & Ackerman's Surgical Pathology Review**. Elsevier Inc., September 2006.

- Chapter 14 "Gallbladder and Extrahepatic Bile Ducts
- Chapter 15 "Pancreas and Periapillary Region
- Chapter 16 "Adrenal Gland and Other Paraganglia"
- Chapter 18 "Male Reproductive System: Prostate and Seminal Vesicles - Testis - Testicular Adnexae – Penis and Scrotum"

3. Pathology textbook translation (four chapters):

In collaboration with Dr. Goran Torlakovic, St. Paul's Hospital, following chapters were translated from English to Croatian (Publisher's approved translation):

“Rosai and Ackerman’s Surgical Pathology”, Elsevier, 9th Edition

- Chapter 1 “Introduction”
- Chapter 2 “Gross Techniques in Surgical Pathology”
- Chapter 3 “Special Techniques in Surgical Pathology”
- Chapter 11 “Gastrointestinal Tract: Esophagus - Stomach – Small bowel”.

4. Review Articles Published on the Internet

A. **Torlakovic EE** . MME (membrane metallo-endopeptidase). Atlas Genet Cytogenet Oncol Haematol. May 2007.

URL : <http://AtlasGeneticsOncology.org/Genes/MMEID41386ch3q25.html>

B. Contributor of review articles for NordiQC Immunohistochemistry Quality Control Group (<http://www.nordiqc.org>)

2005-2006: Major contribution in:

- Epitopes: Cyclin D1 (new) (<http://www.nordiqc.org/Epitopes/CyclinD1/CyclinD1.htm>)
- Epitopes: ALK-1 (new) (<http://www.nordiqc.org/Epitopes/ALK1/ALK1.htm>)
- Epitopes: CD10 (update) (<http://www.nordiqc.org/Epitopes/CD10/CD10.htm>)
- Epitopes: CD23 (update) (<http://www.nordiqc.org/Epitopes/CD23/CD23.htm>)

2003-2004: Major contribution in:

- Preparation and use of positive and negative controls in clinical immunohistochemistry (http://www.nordiqc.org/Techniques/Contol_sections.htm)
- Epitopes: CD15 (<http://www.nordiqc.org/Epitopes/CD15/CD15.htm>)
- Epitopes: CD23 (<http://www.nordiqc.org/Epitopes/CD23/CD23.htm>)
- Epitopes: CD30 (<http://www.nordiqc.org/Epitopes/CD30/CD30.htm>)
- Epitopes: CD34 (<http://www.nordiqc.org/Epitopes/CD34/CD34.htm>)
- Epitopes: S100 (<http://www.nordiqc.org/Epitopes/s-100/s-100.htm>)

2003-2004: Minor contribution in:

- Epitopes: CD117 (<http://www.nordiqc.org/Epitopes/CD117/CD117.htm>)

11. PAPERS IN REFEREED JOURNALS:

1. Jadhav A, **Torlakovic E**, Ndisang JF. Interaction Among Heme Oxygenase, Nuclear Factor- κ B, and Transcription Activating Factors in Cardiac Hypertrophy in Hypertension. Hypertension. 2008 Sep 29. [Epub ahead of print]
2. Gatalica Z and **Torlakovic EE**: Pathology of hereditary colorectal cancer. *Familial Cancer* 2008;7(1):15-26. Epub 2007 Jun 13. Review.
3. **Torlakovic EE** and Snover D. Sessile serrated adenoma; a brief history and

- current status. Review. Critical Reviews in Oncogenesis. 2006 Jul;12(1-2):27-39. Review.
4. **Torlakovic EE**, Slipicevic A, Flørenes VA, Chibbar R, DeCoteau JF, Bilalovic N. Fli-1 expression in malignant melanoma. Histol Histopathol. 2008 Nov;23(11):1309-14.
5. **Torlakovic EE**, Gomez D, Driman DK, Parfitt JR, Wang C, Banerjee T, Snover DC. Sessile serrated adenoma (SSA) vs. traditional serrated adenoma (TSA). Am J Surg Pathol. 2008 Jan;32(1):21-9
6. Aamot HV, **Torlakovic EE**, Eide MB, Holte H, Heim S. Non-Hodgkin lymphoma with t(14;18): clonal evolution patterns and cytogenetic-pathologic-clinical correlations. J Cancer Res Clin Oncol. 2007 Jul;133(7):455-70. Epub 2007 Jan 18.
7. **Torlakovic EE**, Aamot H, Heim S. A marginal zone phenotype in follicular lymphoma with t(14;18) is associated with secondary cytogenetic aberrations typical of marginal zone lymphoma. J Pathol 2006 Jun;209(2):258-64.
8. Ulmer TA, Keeler V, Loh L, Chibbar R, **Torlakovic EE**, Andre S, Gabius HJ, Laferte S. Tumor-associated antigen 90K/Mac-2-binding protein: Possible role in colon cancer. J Cell Biochem. 2006 Aug 1;98(5):1351-66.
9. **Torlakovic EE**, Bilalovic N, Golouh R, Zidar A, Angel S. Prognostic significance of PU.1 in follicular lymphoma. J Pathol. 2006 Jul;209(3):352-9.
10. **Torlakovic EE**, Slipicevic A, Robinson C, DeCoteau JF, Alfsen C, Vyberg M, Chibbar R, Florenes VA. Pax-5 expression in non-hematopoietic tissues. Am J Clin Pathol. 2006 Nov;126(5):798-804.
11. **Torlakovic EE**, Nielsen S, Vyberg M. "Antibody selection in immunohistochemical detection of cyclin D1 in mantle cell lymphoma". Am J Clin Pathol 2005 Nov;124(5):782-9.
12. Vyberg M, **Torlakovic EE**, Seidal T, Risberg B, Helin H, Nielsen S. Nordic immunohistochemical quality control. Croat Med J. 2005;46(3):368-71. Review.
13. Bassarova AV, Nesland JM, Sedloev T, Lilleby W, Hristova SL, Trifonov DY, **Torlakovic EE**. Simultaneous bilateral breast carcinomas: a category with frequent co-expression of HER-2 and ER-a, high Ki-67 and bcl-2 and low p53. Int J Surg Pathol. 2005 Jul;13(3):239-46.
14. Bassarova AV, **Torlakovic EE**, Sedloev T, Hristova SL, Trifonov DY, Nesland JM. Simultaneous bilateral breast carcinoma: Histopathological characteristics and CD44-catenin-cadherin profile. Histol Histopathol. 2005 Jul;20(3):791-9.

15. **Torlakovic EE**, Lilleby W, Berner A, Torlakovic G, Chibbar R, Furre T, Fossa SD. Differential expression of steroid receptors in prostate tissues before and after radiation therapy for prostatic adenocarcinoma. *Int J Cancer*. 2005 Nov 10;117(3):381-6.
16. **Torlakovic EE**, Malecka A, Myklebust JH, Tierens A, Aasheim HC, Nesland JM, Smeland E, Kvaloy S, Delabie J. PU.1 protein expression has a positive linear association with protein expression of germinal centre B cell genes including BCL-6, CD10, CD20 and CD22: identification of PU.1 putative binding sites in the BCL-6 promoter. *J Pathol*. 2005 Jul;206(3):312-9.
17. Torlakovic G, **Torlakovic EE**, Skovlund E, Nesland JM, Reith A, Danielsen HE. Volume-related sequence of tumor distribution pattern in prostate carcinoma: importance of posterior midline crossover in predicting tumor volume, extracapsular extension, and seminal vesicle invasion. *Croat Med J*. 2005 Jun;46(3):429-35.
18. Torlakovic G, Grover VK, **Torlakovic EE**. Easy method of assessing volume of prostate adenocarcinoma from estimated tumor area: using prostate tissue density to bridge gap between percentage involvement and tumor volume. *Croat Med J*. 2005 Jun;46(3):423-8.
19. **Torlakovic EE**, Tenstad E, Funderud S, Rian E. CD10+ stromal cells form B-lymphocyte maturation niches in the human bone marrow. *J Pathol*. 2005 Feb;205(3):311-7.
20. Shoman N, Klassen S, McFadden A, Bickis MG, **Torlakovic EE**, Chibbar R. Reduced PTEN expression predicts relapse in patients with breast carcinoma treated by tamoxifen. *Mod Pathol*. 2005 Feb;18(2):250-9.
21. Schneider EM, **Torlakovic EE**, Stuhler A, Diehl V, Tesch H, Giebel B. The early transcription factor GATA-2 is expressed in classical Hodgkin's lymphoma. *J Pathol*. 2004 Dec;204(5):538-45.
22. **Torlakovic EE**, Bilalovic N, Nesland JM, Torlakovic G, Flørenes VA: ETS-1 transcription factor is widely expressed in benign and malignant melanocytes and its expression has no significant association with prognosis. *Mod Pathol*. 2004 Nov;17(11):1400-6.
23. Bilalovic N, Sanstad B, Golouh R, Nesland JM, Selak I, **Torlakovic EE**. CD10 protein expression in tumor and stromal cells of malignant melanoma is associated with tumor progression. *Mod Pathol*. 2004 Oct;17(10):1251-8.
24. Chibbar R, Shih F, Baga M, **Torlakovic EE**, Ramlall K, Skomro R, Cockcroft DW, Lemire EG. Nonspecific interstitial pneumonia and usual interstitial pneumonia with mutation in surfactant protein C in familial pulmonary fibrosis. *Mod Pathol*. 2004 Aug;17(8):973-80..

25. Torlakovic G, Snover DC, **Torlakovic EE**. Simultaneous EBV-positive lymphoepithelioma-like carcinoma and EBV-negative intestinal type adenocarcinoma in a patient with H. pylori-associated chronic gastritis. *Am J Clin Pathol*. 2004 Feb;121(2):237-43.
26. Bilalovic N, Blystad AK, Golouh R, Nesland JM, Selak I, Trinh D, **Torlakovic EE**. Expression of Bcl-6 and CD10 protein is associated with longer overall survival and time to treatment failure in follicular lymphoma. *Am J Clin Pathol*. 2004 Jan;121(1):34-42.
27. Boudova L, **Torlakovic EE**, Delabie J, Reimer P, Pfistner B, Wiedenmann S, Diehl V, Muller-Hermelink HK, Rudiger T. Nodular lymphocyte predominant Hodgkin lymphoma with nodules resembling T-cell/histiocyte rich B-cell lymphoma: differential diagnosis between nodular lymphocyte predominant Hodgkin lymphoma and T-cell/histiocyte rich B-cell lymphoma. *Blood*. 2003; 102(10): 3753-8. Epub 2003 Jul 24.
28. Linderroth J, Jerkeman M, Cavallin-Stahl E, Kvaloy S, **Torlakovic EE**. Immunohistochemical Expression of CD23 and CD40 May Identify Prognostically Favorable Subgroups of Diffuse Large B-cell Lymphoma: A Nordic Lymphoma Group Study. *Clin Ca Research* 2003 Feb;9(2):722-8.
29. **Torlakovic EE**, Skovlund E, Torlakovic G, Jessurun J, Snover DC, Nesland JM. Morphologic reappraisal of serrated colorectal polyps. *Am J Surg Pathol* 2003 Jan;27(1):65-81.
30. **Torlakovic EE**, Torlakovic G, Brunning RD. Follicular pattern of bone marrow involvement by follicular lymphoma. *Am J Clin Pathol*. 2002;118:780-786.
31. **Torlakovic EE**, Torlakovic G, Nguyen PL, Brunning RD, Delabie J. The value of anti-pax-5 immunostaining in routinely fixed and paraffin-embedded sections: a novel pan pre-B and B-cell marker. *Am J Surg Pathol*. 2002;26:1343-1350.
32. **Torlakovic EE**, Torlakovic G. Follicular colonization by follicular lymphoma. *Arch Pathol Lab Med*. 2002;126:1136-1137.
33. **Torlakovic EE**, Torlakovic G. B-cell markers in lymphocyte predominance Hodgkin's lymphoma. *Arch Pathol Lab Med*. 2002;126:823-828.
34. **Torlakovic EE**, Lilleby W, Torlakovic G, Fosså SD, Chibbar R. In prostate carcinoma expression of estrogen receptor-beta (ER- β) as detected by PPG5/10 antibody has positive association with Gleason score and with expression of androgen receptor (AR). *Human Pathol*. 2002;33:646-651.

Torlakovic, Emina Emilia
Department of Pathology and Laboratory Medicine

CV, Updated 10/2007

35. Torlakovic G, Langholm R, **Torlakovic EE**. CD34/QBEND10 immunostaining in the bone marrow trephine biopsy: A study of CD34-positive mononuclear cells and megakaryocytes. *Arch Pathol Lab Med*. 2002;126:823-828.
36. Tafjord S, Bøhler PJ, Risberg B, **Torlakovic EE**. Estrogen and Progesterone Hormone receptor status in breast carcinoma: Comparison of Immunocytochemistry and Immunohistochemistry. *Diag Cytopathol*. 2002;26:137-141.
37. Jerkeman M, Aman P, Cavallin-Stahl E, **Torlakovic EE**, Akerman M, Mitelman F, Fioretos T. Prognostic implications of BCL6 rearrangement in uniformly treated patients with diffuse large B-cell lymphoma – a Nordic Lymphoma Group study. *Int J Oncol*. 2002;20:161-165.
38. Blystad AK, **Torlakovic EE**, Holte H, Kvaløy S, Lenschow E, Kvalheim G. CD34+ cell enrichment depletes atypical CD30+ cells from peripheral blood progenitor cell grafts in patients with Hodgkin's disease. *Cytotherapy*. 2001;3:295-305.
39. **Torlakovic EE**, Tierens A, Dang, HD, Delabie, J. The transcription factor PU.1, necessary for B-cell development is expressed in lymphocyte predominance, but not classical Hodgkin's disease. *Am J Pathol*. 2001;159:1807-1814.
40. Wiatrowska B, Berner A, Emilsen E, Myklebost G, **Torlakovic EE**. "Cultured anaplastic cell lines as immunocytochemistry controls: a comparison of the ThinPrep®-processed smears and conventional air-dried cytopins". *Diag Cytopathol*. 2001;25:303-308.
41. Lilleby W, Torlakovic G, **Torlakovic EE**, Skovlund E, Fosså SD. Prognostic significance of histological grading for patients with prostate cancer who are assessed by Gleason and WHO grading systems in needle biopsies obtained prior to radiotherapy. *Cancer*. 2001;92:311-319.
42. Davidson B, Risberg B, Berner A, Smeland EB, **Torlakovic EE**. Evaluation of lymphoid cell populations in cytology specimens using flow cytometry and polymerase chain reaction. *Diag Mol Pathol*. 1999 ;8(4):183-8.
43. Blystad A, Kvalheim G, **Torlakovic EE**, Holte H, Jacobsen E, Beiske K, Valerhaugen H, Lenschow E, Kvaloy S. High-dose therapy supported with immunomagnetic purged autologous bone marrow in high-grade B cell non-Hodgkin's lymphoma. *Bone Marrow Transplant*. 1999;24(8):865-872.
44. **Torlakovic EE**, Berner A, Risberg B. Detection of immunoglobulin heavy chain gene rearrangements by PCR analysis on lymph node imprints and fine needle aspirate smears: A comparison of five different imprint preparations. *Diag Cytopathology*. 1999;20:333-338.

45. Kennedy BJ, Torkelson JL, **Torlakovic EE**. Uracil mustard revisited. *Cancer*. 1999;85:2265-2272.
46. Froberg MK, Brunning RD, Dorion P, Litz CE, **Torlakovic EE**. Demonstration of clonality in neutrophils using FISH in a case of chronic neutrophilic leukemia. *Leukemia*. 1998; 12:623-626.
47. Gipson IK, Ho SB, Spurr-Michaud SJ, Tisdale AS, Zhan Q, **Torlakovic EE**, Pudney J, Anderson DJ, Toribara NW, Hill JA 3rd. Mucin genes expressed by human female reproductive tract epithelia. *Biol Reprod*. 1997;56:999-1011.
48. **Torlakovic EE**, Cherwitz DL, Jessurun J, Scholes J, McGlennen R. B-cell gene rearrangement in benign and malignant lymphoid proliferations of mucosa-associated lymphoid tissue (MALT) and lymph nodes. *Hum Pathol*. 1997;28:166-173.
49. **Torlakovic EE**, Snover DC. Serrated adenomatous polyposis. *Gastroenterology*. 1996;110:748-755.
50. **Torlakovic EE**, Hibbs JT, Miller JS, Litz Ce. Intracellular bacteria in routine peripheral blood smears in patients with central venous catheters. *Arch Int Med*. 1995;155:1547-1550.
51. **Torlakovic EE**, Litz CE, McClure JS, Brunning RC. Direct detection of Philadelphia chromosome in CD-20 positive lymphocytes in chronic myeloid leukemia by tri-color immunophenotyping/FISH. *Leukemia*. 1994;8:1940-1943.
52. **Torlakovic EE**, Ames ED, Manivel JC, Stanley M. Cytology of myoepithelial lesions: Case reports and review of the literature. *Diag Cytopathol*. 1993;9:655-660.
53. **Torlakovic EE**, Clayton F, Ames ED. Refractive mycobacteria in Romanowsky-stained bone marrow smears: A comparison of acid-fast-stained tissue section of Romanowsky-stained smears. *Am J Clin Pathol*. 1992;97:318-321.
54. Clayton R, Reka S, Cronin WJ, **Torlakovic EE**, Sigal SH, Kotler DP. Rectal mucosal pathology varies with human immunodeficiency virus antigen content and disease stage. *Gastroenterology*. 1992;103:919-933.

12. PAPERS IN NON-REFEREED JOURNALS:

Torlakovic E. National Standards Committee, CAP Newsletter, May 2008.

13. ABSTRACTS (PEER-REVIEWED):

Torlakovic, Emina Emilia
Department of Pathology and Laboratory Medicine

CV, Updated 10/2007

1. Jünger A, Fibich C, voralia M, Neufeld H, Doell H, DeCoteau J, **Torlakovic E**. Microenvironmental Colocalization of CD10-positive dendritic bone marrow stromal cells at diagnosis predicts survival after autologous stem cell transplantation in multiple myeloma. USCAP Annual Meeting, March 1-7, Denver, Colorado, USA (Mod Pathol 2008;January, Suppl 1)
2. **Torlakovic EE**, Amot H, Fesser J, Heim S, van den Berghe J, Kusalik A. Random chromosomal aberrations are not random. 15th Annual International Conference on Intelligent Systems for Molecular Biology (ISMB) & 6th European Conference on Computational Biology (ECCB). Vienna, Austria: July 21-25, 2007.
3. **Torlakovic EE**, Fibich C, Angel S, Voralia M, DeCoteau JF. Plasmacytoid differentiation in chronic lymphocytic leukemia. Canadian Association of Pathologists Annual Meeting, June 9-14 2007, Toronto, Ontario, Canada Platform Presentation.
4. Wang C, **Torlakovic EE**, Keeler V, Banerjee T, Laferté S. Cyclophilin C-associated protein (CyCAP) null mice: A model of experimental mucosal hyperplasia of the colon. Canadian Association of Pathologists Annual Meeting, June 9-14 2007, Toronto, Ontario, Canada.
5. Bahzad S, Gilks B, Klassen S, **Torlakovic EE**. Building Canadian immunohistochemistry quality control (ciQC). Canadian Association of Pathologists Annual Meeting, June 9-14 2007, Toronto, Ontario, Canada.
6. **Torlakovic EE**, Gomez JD, Banerjee T, Wang C, Gatalica Z, Snover CD. Serrated adenomas of the large intestine: Loss of crypt anchoring is a defining feature of traditional versus sessile serrated adenomas. USCAP 2007 Annual Meeting, San Diego. Published in: Mod Pathol. 2007 Suppl, Abstract no. 590 Platform Presentation
7. Takahashi M, Pastural E, Lowsky R, **Torlakovic EE**, Czader M, Garcia-Manero G, Amin HM, Geyer CR, DeCoteau J. RIZ1 Is Downregulated during CML Progression and Displays Tumor Suppressor Properties in CML Cell Lines. Published in: Blood (ASH Annual Meeting Abstracts), Nov 2006; 108: 2134.
8. B Coleman, M Czader, **EE Torlakovic**, J Henley, A Orazi. How to distinguish precursor T-Cell Lymphoblastic Lymphoma from Lymphocyte-Rich Subtypes of Thymomas: A role for immunohistochemistry? Published in: Mod Pathol JAN 2006, USCAP Abstract no. 1088.
9. Vyberg M, Nielsen S, **Torlakovic EE**. Nordic immunohistochemical quality control (NordiQC). IAP XXVI Congress. Published in: Mod Pathol 2006, Suppl. Abstract 602.
10. **Torlakovic EE**, Slipicevic A, Robinson C, DeCoteau JF, Alfsen C, Vyberg M, Chibbar R, Florenes VA. Diagnostic value of Pax-5 expression in non-

Torlakovic, Emina Emilia
Department of Pathology and Laboratory Medicine

CV, Updated 10/2007

hematolymphoid tissues. IAP XXVI Congress. Published in: Mod Pathol 2006, Suppl. Abstract 601.

11. **Torlakovic EE**, Slipicevic A, Florenes V, Chibbar R, Bilalovic N. Fli-1 expression in malignant melanoma. USCAP Abstracts. United States and Canadian Academy of Pathology, Annual Meeting, Feb 11-Feb20, 2006, Atlanta, GA, USA. Published in: Mod Pathol 2006, January Suppl.
12. Au N, **Torlakovic EE**, Dupuis B, Gale N, Gilks B, Dalal B, Coupland R. Bone marrow tissue microarrays are effective tools for quality assurance of immunohistochemistry staining. UBC Pathology Day , May 26, Vancouver, BC, 2006.
13. **Torlakovic EE**, Aamot H, Heim S. Secondary Cytogenetic Aberrations Characteristic of Marginal Zone Lymphoma in Follicular Lymphoma with t(14;18)(q32;q21) and Their Association with Marginal Zone Morphologic Phenotype. Published in: Mod Pathol. 2005, January Suppl.
14. **Torlakovic EE**, Bilalovic N, Golouh R, Nesland JM. Prognostic Significance of Germinal Center (GC) Phenotype for Outcome in Follicular Lymphoma. Published in: Mod Pathol. 2005 Suppl , Abstract no. 1175 Platform Presentation
15. **Torlakovic EE**, Malecka A, Myklebust JH, Tierens A, Aasheim H-C, Nesland JM, Smeland E, Kvaløy S, Delabie J. PU.1 Binds to the BCL-6 Promotor and Is Co-Upregulated with Bcl-6 in Germinal Center B-Cell Development and Germinal-Center Cell-Derived B-Cell Lymphoma. Published in: Mod Pathol. 2005 Suppl, Abstract no. 1174. Platform Presentation
16. El-Zimaity HMT, Wotherspoon A, de Jong D, Stolte M, Savio A, de Mascarel A, **Torlakovic EE**. Houston MALT lymphoma Workshop; Interobserver variation in the histopathological assessment of MALT/MALT lymphoma: Towards a Consensus. EUROPEAN HELICOBACTER STUDY GROUP, XVII International Workshop Gastrointestinal, Pathology and Helicobacter, Sept 22 - 24, 2004, Vienna, Austria. Platform Presentation
17. Shoman N, Klassen S, McFadden A, Bickis M, **Torlakovic EE**, Chibbar R. Downregulation of PTEN expression predicts relapse in patients with breast carcinoma treated by tamoxifen. 55th Annual Meeting of the Canadian Association of Pathologists, July 3-7, 2004 • Montréal, Québec, Canada.
18. Aamot HV, **Torlakovic EE**, Heim S. Non-Hodgkin lymphoma with t(14;18): Clonal evolution patterns and cytogenetic-pathologic correlations. Lymphoma & Myeloma 2004, Oct 2004, New York, New York.
19. Josefsen D, Tzvetanov L, Lona T, Dyrhaug M, Lenschow E, **Torlakovic EE**, Nesland JM, Kvalheim G. Properties of bone marrow derived mesenchymal- and

endothelial cells cultured ex vivo in AastromReplicell system. Published in: *Blood* 102 (11): 4419 Part 2 Nov 16 2003.

20. El-Zimaity H, Wotherspoon A, deMascarel A, Savio A, Stolte M, **Torlakovic EE**, Younes M, Applemen H, Cherian R, Copie-Bregman C, de Jong D, Dixon M, Greenson J, Isaacson P, Muller-Hermelink HK, ota H, Ruggae M. Interobserver Variation in the Histopathological Assessment of MALT/MALT Lymphoma. United States and Canadian Academy of Pathology 2004 Annual Meeting. Published in: *Mod Pathol* 2004;17(Supplement 1):114A.
21. Bilalovic N, Blystad AK, Golouh R, Nesland JM, Selak I, **Torlakovic EE**. Follicular Lymphoma Grading by Mann and Berard are Predictive of Overall Survival and Time to Treatment Failure, however, only Grade 1 has favorable OS and TTF. Published in: *Virch Arch* 2003;443:275. Platform Presentation
22. Bilalovic N, Blystad A.K, Golouh R, Nesland J.M, Selak I, **Torlakovic EE**. BCL-6 and CD10 Protein Expressions are Prognostic Factors of Overall Survival and Time to Treatment Failure in Follicular Lymphoma. Published in: *Virch Arch* 2003;443:275. Platform Presentation
23. Bilalovic N, Sandstad B, Golouh R, Nesland JM, Selak I, **Torlakovic EE**. In Malignant Melanoma CD10 Protein Expressions are Associated With Metastatic Tumors Higher Clark Levels and Tumor Thickness According to Breslow. Published in: *Virch Arch* 2003;443:285. Platform Presentation
24. Torlakovic G, **Torlakovic EE**, Skovlund E, Nesnald JM, Reith A, Danielsen H. Volume-Related Patterns of Tumor Distribution of Prostate Carcinoma. United States and Canadian Academy of Pathology, 92nd Annual Meeting, March 22-28, 2003, Washington DC, USA. Published in: *Mod Pathol* 2003;16:173A.
25. **Torlakovic EE**, Linderorth J, Jerkeman M, Cavallin-Sthl E, Kvaloy S. Expression of CD40 in Diffuse Large B Cell Lymphoma Is Associated with Longer Overall Survival and Time to Treatment Failure: Possible Proapoptotic Role of CD40 Via Induction of Bax. United States and Canadian Academy of Pathology, 92nd Annual Meeting, March 22-28, 2003, Washington DC, USA. Published in: *Mod Pathol* 2003;16:256A.
26. **Torlakovic EE**, Linderorth J, Jerkeman M, Kvaloy S. Intratumoral T Cells and Aberrant Expression of T Cell Antigens in Diffuse Large B Cell Lymphoma. United States and Canadian Academy of Pathology, 92nd Annual Meeting, March 22-28, 2003, Washington DC, USA. Published in: *Mod Pathol* 2003;16:255A.
27. **Torlakovic EE**, Linderorth J, Jerkeman M, Kvaloy S. Expression of Pan B Cell Antigens in Diffuse Large B Cell Lymphoma: Potential Implications for Prognosis and Immunotherapy. United States and Canadian Academy of Pathology, 92nd Annual Meeting, March 22-28, 2003, Washington DC, USA. Published in: *Mod Pathol* 2003;16:255A.

28. Boudova L, Rüdiger T, **Torlakovic EE**, Delabie J, Müller-Hermelink HK. Nodular Growth Pattern in T-Cell/histocyte Rich B-Cell Lymphoma: A problem in the differential diagnosis to lymphocyte predominance Hodgkin's lymphoma. Fifth International Symposium on Hodgkin's lymphoma. 2001, Cologne, Germany. Published in: J Clin Pathol 2002;55(Suppl 1):O41. Platform Presentation
29. **Torlakovic EE**, Linderroth J, Jerkeman M, Kvaløy S, and Delabie J. Expression of the B-cell Transcription Factor PU.1 is strongly correlated with CD10, CD79a, CD20, CD22, and bcl-6 expression in diffuse large B-Cell Lymphoma (DLBCL). Published in: Blood , ASH Abstracts, 2001.
30. **Torlakovic EE**, Anne Tierens, M.D., Ph.D., Hien D. Dang, M.Sc., and Jan Delabie, M.D., Ph.D. The Transcription Factor PU.1, Necessary for B-cell development is expressed in Lymphocyte Predominance, but not classical Hodgkin's Disease. Fifth International Symposium on Hodgkin's Lymphoma. 2001, Cologne, Germany. Published in: J Clin Pathol 2002;55(Suppl 1).
31. Lilleby W, Torlakovic G, **Torlakovic EE**, Skovlund E, Fosså SD. Prognostic significance of histological grading for patients with Prostate Cancer assessed by Gleason and WHO Grading Systems in Pre-Radiotherapy needle biopsies. 90th Annual meeting, USCAP, 2001, Atlanta, GA, U.S.A. Published in: Mod Pathol 2001;14:115A.
32. **Torlakovic EE**, Skovlund E, Snover DL, Torlakovic G, Jessurun J, Nesland JM. Morphologic reappraisal of serrated colorectal polyps. 90th Annual meeting, USCAP, 2001, Atlanta, GA, U.S.A. Published in: Mod Pathol 2001;14:96A.
33. **Torlakovic EE**, Thorstensen L, Lothe RA, Nesland JM. Allelic Imbalance on Chromosome Arm 1p, DNA Microsatellite Instability and *K-RAS* Mutations in Hyperplastic Polyps of the Colorectum: Left vs. Right and Small vs. Large. 90th Annual meeting, USCAP, 2001, Atlanta, GA, U.S.A. Published in: Mod Pathol 2001;14:97A.
34. Wiatrowska BA, Berner A, Emilsen E, Mykelbost GL, **Torlakovic EE**. ThinPrep Processed, Cultured Anaplastic Cell Lines as Immunocytochemistry Controls. 27th European Congress of Cytology, Lillehammer, Norway, 2000.
 - a. **Best Abstract Award** at 27th European Congress of Cytology, Lillehammer, Norway, 2000.
35. Blystad AK, **Torlakovic EE**, Holte H, Pharo A, Lenschow E, Jacobsen E, Rusten L, Kvaløy S and Kvalheim G. CD34+ Cell enrichment efficiently remove Atypical CD30+ cells from PBPC products in patients with relapsed Hodgkin's Disease. Published in: Cytotherapy 1999, Vol 1, No 3, p 250, P 050.
36. Blystad AK, **Torlakovic EE**, Holte H, Pharo A, Lenschow E, Jacobsen E, Rusten L, Kvaløy S and Kvalheim G. CD34+ Cell enrichment efficiently remove atypical

Torlakovic, Emina Emilia
Department of Pathology and Laboratory Medicine

CV, Updated 10/2007

CD30+ Cells from PBPC products in patients with relapsed Hodgkin's disease.
Published in: *Bone Marrow Transpl* 1999;23(Suppl.1):S146.

37. Blystad AK, **Torlakovic EE**, Holte H, Gilen E, Lenschow E, Kvaløy S and Kvalheim G. Peripheral Blood Progenitor Cells from patients with relapsed Hodgkin's Disease contain high numbers of atypical CD30+ Cells. Published in: *ASH Abstracts, Blood* 1998;92(Suppl.1):309b.
38. Blystad AK, Kvalheim G, **Torlakovic EE**, Holte H, Jacobsen E, Beiske K, Vålerhaugen H, Lenschow E and Kvaløy S. High-dose therapy supported with immunomagnetic purged autologous bone marrow in High-Grade B Cell Non-Hodgkin's Lymphoma. Published in: *Bone Marrow Transpl* 1999;24:865-872.
39. Davidson B, Risberg B, Berner A, Smeland E, **Torlakovic EE**. Evaluation of Lymphoid Cell Populations in Cytology Specimens. A comparative study using flow cytometry and polymerase chain reaction. 46th Meeting of the American Society for Cytolopathology, Neshville, TN, November 1998. Published in: *ACTA Cytol* 1998;42(2):374-6.
40. **Torlakovic EE**, Berner A, Risberg B. Detection of immunoglobulin heavy chain gene rearrangements by PCR analysis on lymph node imprints and fine needle aspirate smears: A Comparison of Five Different Imprint Preparations. 25th European Society for Clinical Cytology, Oxford, UK.
41. Jessurun J, Alonso-de-Ruiz P, **Torlakovic EE**, Perrone T, Manivel JC, Duggan M. Papilloma virus infection in penile biopsy specimens. Histologic correlation with PCR analysis. U.S. and Canadian Academy of Pathology, San Francisco 1994. Published in: *Lab Invest* 1994;70:77A.
42. **Torlakovic EE**, Jessurun J, McGlennen R. Patterns of B and T-cell gene rearrangements in chronic diseases of the colon. Poster, U.S. and Canadian Academy of Pathology, San Francisco 1994. Published in: *Lab Invest* 1994;70:68A.
43. **Torlakovic EE**, Snover DC. So-called "Giant Hyperplastic Polyposis Syndrome" Associated with Adenocarcinoma: A light microscopic and immunohistochemical comparison with neoplastic and hyperplastic polyps. U.S. and Canadian Academy of Pathology, San Francisco 1994. Published in: *Lab Invest* 1994;70:67A. Platform Presentation

14. TECHNICAL REPORTS RELEVANT TO ACADEMIC FIELD:

1. **Torlakovic EE**. Letter to the editor. Re: PU.1 protein expression has positive linear association with protein expression of germinal centre B cell genes

Torlakovic, Emina Emilia
Department of Pathology and Laboratory Medicine

CV, Updated 10/2007

including BCL-6, CD10, CD20 and CD22: Identification of PU.1 putative binding sites in the BCL-6 promotor. J Pathol. 2006 Sep;210(1):130-1.

2. **Torlakovic EE.** Letter to the editor. Le lymphome imaginaire. Hum Pathol. 1999 May;30(5):594-5.
3. **Torlakovic EE.** Letter to the editor. The presence of the Ph-chromosome in different cell lineages in CML. Br J Haematol. 1997 Dec;99(3):707-8.
4. **Torlakovic EE,** Ames ED. Letter to the editor. Mycobacteria on Wright's-stained smears. Am J Clin Pathol. 1991 Aug;96(2):290.

15. BOOK REVIEWS:

1. Schumacher Harold R, Rock William A, Jr., Stass, Sanford A: HANDBOOK OF HEMATOLOGIC PATHOLOGY, Marcel Dekker, Inc., New York, 2000. Modern Pathology 2000;113:1205.
2. Faguet GB. HEMATOLOGICAL MALIGNANCIES. METHODS AND TECHNIQUES. Humana Press, NJ, 2001. Modern Pathology 2000.

16. INVITED LECTURES OUTSIDE U OF S AND INVITED CONFERENCE PRESENTATIONS:

“The need for European external quality assurance program for bone marrow immunohistochemistry”, European Bone Marrow Working Group (EBMWG) Scientific and Business Meeting, Athens, 4-6 October 2007

“The role of CD10-positive dendritic cells for biology of multiple myeloma”, European Bone Marrow Working Group (EBMWG) Scientific and Business Meeting, Athens, 4-6 October 2007

“Standardization in Bone Marrow Immunohistochemistry”, European Bone Marrow Working Group (EBMWG) Meeting, Paris, France, November 2005.

“CD10-positive Dendritic Cells Form Developmental Niche for Maturing B-lymphocytes”, European Bone Marrow Working Group (EBMWG) Meeting, Karolinska Institute, Stockholm, Sweden, June 2004.

“The Role of Extralaboratory Quality Control in Diagnostic Immunohistochemistry: Current International Trends”, Invited by Canadian Coalition for Quality Control, Canadian Coalition for Quality Control Annual Meeting, Halifax, May 2005.

“Quality Control in Diagnostic Immunohistochemistry”, Invited by Canadian Coalition for Quality Control, Canadian Coalition for Quality Control Annual Meeting, Saskatoon, May 2004.

“Immunohistochemistry in Tumor Classification and Phenotyping. Planning of Antibody Panels and Quality Assurance of Stainings.” Invited by Danish Society for Cytochemistry and Histochemistry, May 2004.

“Transcription Factors in Diagnostic Immunohistochemistry”, NordiQC Immunohistochemistry Seminar, Oslo, Norway, November 2001.

“Immunohistochemistry in Bone Marrow Pathology”, NordiQC Immunohistochemistry Seminar, Oslo, Norway, November 2001.

“Immunocytochemistry: Art or Laboratory Routine?” NordiQC Immunohistochemistry Seminar, Oslo, Norway, November 2001.

“Immunohistochemistry vs. Flow Cytometry in Evaluation of Bone Marrow Biopsy”, Invited by the Norwegian Hematology Association, Annual Meeting of The Norwegian Association of Hematologists, December 2000.

“Special Studies in Evaluation of Bone Marrow Biopsy; Necessity for Molecular, Cytogenetic, and Flow Cytometric Analyses.”, Seminar in Hematopathology, The Norwegian Radium Hospital, Oslo, Norway, September 1998.

17. RESEARCH AND PROJECT GRANT INFORMATION:

A. Peer Reviewed Grants

1. Principal Investigator. Technology Enhanced Learning Grant/Support for Course Development: “Application of Virtual Microscopy in Pathology and Anatomy and Cell Biology Courses.” (\$31,850)
2. University of Saskatchewan Vice-Provost Capital Equipment Start-up Funds (Supplement) (\$18,000).
3. Principal investigator: Royal University Hospital (RUH) Foundation Innovation Fund: “Role of CD10 expression in multiple myeloma” (\$5,000).
4. Principal investigator: Royal University Hospital (RUH) Foundation Foundation Fund: “Sessile Serrated Adenoma” (\$24,850).
5. Co-applicant (principal investigators: John DeCoteau and Ron Geyer) SHRF: 2005-06 : Research Group Development Grant (year 1: 25,000 CAD, year 2: 25,000, total: \$50,000).
6. Principal investigator: SHRF New Investigator Grant 2006 (year 1: 38,500 CAD, year 2: 38,500, total: \$78,000).

Torlakovic, Emina Emilia
Department of Pathology and Laboratory Medicine

CV, Updated 10/2007

7. SHRF Equipment Grant 2006 (\$28,500).
8. Torlakovic, E and Litz C. "Detection of bcr-abl translocation by RT/PCR in situ", Minnesota Medical Foundation Young Investigator Research Grant 1995 (\$4,000 USA).

B. Non-Peer Reviewed Grants

1. USTEP grant for the Summer Student Position (\$2300.00)
2. Torlakovic, E: "Canadian Immunohistochemistry Quality Control – cIQc". Funding Source: U of S (\$5,000).
3. Torlakovic, E: "The role of GATA transcription family in diagnostic pathology". Funding Source: U of S (\$5,000).
4. Torlakovic, E and DeCoteau J. Tumor Bank Establishment (Freezers). Funding Source: Saskatchewan Cancer Agency; Health Research Division and College of Medicine (total \$20,000).
5. University of Saskatchewan Vice-Provost Equipment Start-up Funds (\$12,000).

18. PROFESSIONAL PRACTICE:

A. Professional Practice

SDH: Department of Pathology and Laboratory Medicine: Quality Assurance/Quality Control Activities:

- Introduction, development and implementation of the QC Program for Immunocytochemistry for Department of Pathology, SDH, Saskatoon (2005/2006):
 - Introduction of cell culture system for positive controls.
 - Implementation of improvements in cell block preparation technique to enable tissue collection, preservation, and optimal medium for immunophenotyping with decreased cost.
- Assessment of current status and proposal for future departmental clinical practice development (2005/2006): Introduction of Fluorescent In Situ Hybridization (FISH) for Applications in Diagnostic Hematopathology;
- Tissue Processing: Bone Marrow Core Biopsy Processing; Current Status and Implementation of Cost-Effective Measures (2005/2006)
- Tissue Processing: Lymph Node Biopsy Tissue Processing (2007/2008)

**SDH: Department of Pathology and Laboratory Medicine:
Implementation of Cost-Effective Measures in Diagnostic
Immunohistochemistry:**

- The review of the antibody quality and cost followed by replacement of series of antibodies by higher quality antibodies with lower price.
- Selection and implementation of cost-effective “open system” automated immunostainers, which provide higher quality, lower price, shorter turn around time, and clinical flexibility to choose up-to-date detection systems in the future.
- Clinical Immunohistochemistry Handout (Update 2004): Development of intradepartmental practice guidelines for Immunohistochemistry:, Jan 2004 (Fifth Edition)

B. Continuing Medical Education

1. Director: “**Seminar in Hematopathology**”, The Norwegian Radium Hospital, Oslo, Norway, September 1998 (65 participants).
2. Director: “**NordiQC Seminar in Diagnostic Immunohistochemistry**” Radisson Hotel, Oslo, Norway, November 2001 (145 participants).
3. Director: “**W403: Diagnostic Immunohistochemistry: A Practical Approach to Common Problems**”, CAP Annual Meeting, June 10th 2007, Toronto, ON (22 participants).
4. Director: “**W305: Diagnostic Immunohistochemistry: A Practical Approach to Common Problems**”, CAP Annual Meeting, July 12th 2008, Ottawa, ON (32 participants).

C. Manuscript Review for Journals (ad hoc)

- Histopathology
- Journal of Clinical Pathology
- Journal of Pathology
- Br Journal of Hematology
- Helicobacter
- Int Journal of Cancer
- Ultrastructural Pathology
- BMC Urology
- BMC Cancer Therapy
- Asian Journal of Andrology
- Cancer Therapy
- Medical Science Monitor
- Modern Pathology

Torlakovic, Emina Emilia
Department of Pathology and Laboratory Medicine

CV, Updated 10/2007

- World Journal of Pediatrics
- Journal of Medical Sciences Res
- BMC Cancer
- Journal of Immunological Methods
- Canadian Medical Association Journal

Member of Editorial Board:

- Critical Reviews in Oncogenesis, Begell House, Belgium (2006-Present)

D. Grant Reviews

- Saskatchewan Health Research Foundation: 3 (New Investigator Fund /2008)
- RUH Foundation Fund 2006: 12
- Northridge Dev. Innovation Fund 2006: 4
- Melfort Union Hospital's *Ralston Brothers* Medical Research Fund 2008: 11
- Ministry of Health and Research, Republic of Croatia (May 2006):
 - "The role of EBV in Hodgkin Lymphoma, Prognostic Considerations"

19. CONSULTING WORK UNDERTAKEN:

- Expert Consultant to Canadian Cancer Agency, New Foundland and Labrador Division: "Estrogen Receptor Testing in Breast Carcinoma Inquiry" (2008).
- Consultant Member of Gerson Lehrman Group Council (March 2007 – present)
- "iPath" Consultant: "Hematopathology Group" (Fall 2006 – present)
 - iPath is a telemedicine consultation in pathology developed by University of Basel, Switzerland, Europe in order to help diagnostic services to underdeveloped countries.

20. DEPARTMENTAL AND COLLEGE COMMITTEES:

A. Current Committee Membership

- **Chair**, Clinical Immunohistochemistry Committee, Department of Pathology (2004-present).
- **Chair**, Tumor Bank Committee, Department of Pathology (2005-present).
- **Member**, Health Sciences Library Committee (2006-present)
- **Member**, Research/Graduate Studies Committee (2006-present)
- **Member**, Gender and Equity Committee (2006-present)
- **Member**, Endowment Fund Committee (July 2007)

21. UNIVERSITY COMMITTEES (U OF S):

A. Current Committee Membership

- **Member**, Charitable Donations Committee (2007-present).
- **Member-at-Large**, College of Medicine Faculty Council (July 1st 2008)

22. PROFESSIONAL AND ASSOCIATION OFFICES AND COMMITTEE ACTIVITY OUTSIDE THE UNIVERSITY:

1. **Member of Expert Panel** "Guidelines on Hormone Receptor Testing in Breast Cancer", American Society of Clinical Oncology and College of American Pathologists (**ASCO&CAP Expert Panel**) (July 2008-Present)
2. **Expert Member**, "The Guideline of Hormone Testing in Breast Cancer" by Cancer Care Ontario's Program in Evidence-Based Care (PEBC) (September 2008-Present).
3. **Member-at-Large**, Executive Committee, Canadian Association of Pathologists (July 2008-present).
4. **Chair**, European Bone Marrow Immunohistochemistry Group Session, London, UK, March 15th, 2008.
5. **Chair**, National Standards Committee/Immunohistochemistry, Canadian Association of Pathologists (Spring 2007-present).
6. **Principal Organizer and Director** (in collaboration with Dr. Gilks Blake from BC): The first Canadian extralaboratory immunohistochemistry quality assurance/quality control group: "**Canadian Immunohistochemistry Quality Control Group**", cIQc; www.cIQc.ca , (2006-present).
7. **Member**, European Bone Marrow Working Group, European Hematopathology Association, (2003-present).
8. **Member**, International Review Working Group on Serrated Polyps of the Colorectum: Reproducibility Study, (01/2007-01/2008).
9. **Norwegian representative**, Aplastic Anemia/Hypoplastic MDS, Scandinavian Review Group (2000-2003).
10. **Norwegian representative and Member of Executive Committee/Core Group of NordiQC**, Scandinavian Quality Control Group for Immunohistochemistry (www.nordiQC.org) (1999-2003).

23. MEMBERSHIP IN PROFESSIONAL ASSOCIATIONS:

- Member**, Canadian Association of Pathologist (2005-present).
- Member**, Canadian Medical Association (2004-present).
- Member**, Saskatchewan Medical Association (2004-present).
- Member**, Saskatchewan Association of Pathologist (2004-present).
- Member**, Canadian Medical Protective Association (2003-present).
- Member**, International Academy of Pathology&USCAP (1999-present).
- Member**, Society for Hematopathology (2000-present).

Torlakovic, Emina Emilia
Department of Pathology and Laboratory Medicine

CV, Updated 10/2007

- Member**, Norwegian Medical Association (1998-2004).
- Member**, Norwegian Pathology Association (1998-2004).
- Member**, Norwegian Hematology Association (1999-2004).
- Junior Member**, College of American Pathologist (1994-1996).
- Junior Member**, American Society for Clinical Pathology (1994-1996).
- Junior Member**, American Medical Association (1992-1996).
- Member**, Croatian Medical Association (1986-1989).